AFCM
VRTX icon

Applied Finance Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Applied Finance Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,106
Closed -$955K – 234
2025
Q4 		$955K Buy
+2,106
New +$908K 0.07% 105
2025
Q2 		– Sell
-3,459
Closed -$1.68M – 365
2025
Q1 		$1.68M Buy
3,459
+439
+15% +$205K 0.12% 74
2024
Q4 		$1.22M Buy
3,020
+191
+7% +$88.5K 0.05% 89
2024
Q3 		$1.32M Sell
2,829
-77
-3% -$37K 0.06% 91
2024
Q2 		$1.36M Buy
+2,906
New +$1.26M 0.06% 79

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Applied Finance Capital Management's VRTX Position: Q1 2026 in Review

Applied Finance Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 2,106 shares — an estimated $955K sold.

Applied Finance Capital Management first reported a position in VRTX in Q2 2024 and held it in 5 quarters. The position peaked at $1.68M in Q1 2025. 1,699 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Applied Finance Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Applied Finance Capital Management sold 2,106 Vertex Pharmaceuticals shares in Q1 2026, an estimated $955K.
  • Applied Finance Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • Applied Finance Capital Management's Vertex Pharmaceuticals position peaked at $1.68M in Q1 2025.
  • 1,699 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Applied Finance Capital Management's 13F filing for Q1 2026, filed 4 May 2026.